Case studies

Dr Silvia Vilarinho and Dr Deepak Joshi reflect on the highlights from EASL Congress 2026, focusing on late‑onset genetic cholestasis and new insights in Alagille syndrome. They discuss the expanding role of genomic testing in adults, the move toward multidisciplinary Genetic Grand Rounds, and emerging IBAT‑targeted therapies and pregnancy data that are changing diagnosis and management.

Carola Dröge and Verena Keitel-Anselmino discuss IBAT inhibitor therapy in adults with hereditary BSEP-deficiency at EASL 2026.

Real-world data show promise for IBAT inhibitor use in adults with late-onset PFIC and women with ICP.

Researchers evaluate the incidence of intrahepatic cholestasis of pregnancy recurrence and identify potential predictors.

Jeremy Nayagam highlights research on genetic testing in adults with unexplained cholestatic liver disease and hepatitis and explains why such testing is important in the diagnosis of these patients.

Clinical data suggest comparable IBAT inhibitor response for adults with hereditary BSEP deficiency as seen in pediatric trials.

A targeted next generation sequencing gene panel could offer a definitive diagnosis for some adults with unexplained cholestasis.

Intrahepatic cholestasis of pregnancy significantly increases the risk for developing hepatobiliary morbidity.